Retinitis Pigmentosa represents a group of genetic disorders that cause progressive vision loss via degeneration of pho8
toreceptors, but there is in principle no treatment available. For any therapy development, a deeper comprehension of the dis9
ease-leading mechanism(s) at the molecular level is needed. Here we focused on the cGMP-PKG system, which has been suggested
10 to be a driver in several models of the disease. To gain insights in its downstream signaling we manipulated the cGMP-PKG system
11 with the aid of organotypic retinal explant cultures from either a mouse-based disease model, i.e. the rd1 mouse, or its healthy
12 wild-type counterpart (wt), by adding different types of cGMP analogues to either inhibit or activate PKG in retinal explants from
13 rd1 and wt, respectively. An RNA sequencing was then performed to study the cGMP-PKG dependent transcriptome. Expression
14 changes of gene sets related to specific pathways or functions, that fulfilled criteria involving that the changes should match PKG
15 activation and inhibition, were determined via bioinformatics. The analyses highlighted that several gene sets linked to oxidative
16 phosphorylation and mitochondrial pathways were regulated by this enzyme system. Specifically, the expression of such pathway
17 components was upregulated in the rd1 treated with PKG inhibitor and downregulated in the wt with PKG activator treatment,
18 suggesting that cGMP-PKG act as a negative regulator in this context. Downregulation of energy production pathways may thus
19 play an integral part in the mechanism behind the degeneration for at least several RP mutations.
This work is funded by EU H2020 Research & Innovation Programme - Marie Sklodowska-Curie Actions - ETN - transMed - 765441.